[go: up one dir, main page]

WO2007009701A3 - Use of substituted pyrazole compounds and combinations thereof for the treatment of the metabolic syndrome - Google Patents

Use of substituted pyrazole compounds and combinations thereof for the treatment of the metabolic syndrome Download PDF

Info

Publication number
WO2007009701A3
WO2007009701A3 PCT/EP2006/006975 EP2006006975W WO2007009701A3 WO 2007009701 A3 WO2007009701 A3 WO 2007009701A3 EP 2006006975 W EP2006006975 W EP 2006006975W WO 2007009701 A3 WO2007009701 A3 WO 2007009701A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
metabolic syndrome
combinations
pyrazole compounds
substituted pyrazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2006/006975
Other languages
French (fr)
Other versions
WO2007009701A2 (en
Inventor
Helmut H Buschmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Esteve Pharmaceuticals SA
Original Assignee
Laboratorios del Dr Esteve SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP05384014A external-priority patent/EP1743637A1/en
Application filed by Laboratorios del Dr Esteve SA filed Critical Laboratorios del Dr Esteve SA
Publication of WO2007009701A2 publication Critical patent/WO2007009701A2/en
Publication of WO2007009701A3 publication Critical patent/WO2007009701A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to the use of substituted pyrazole compounds for the treatment of metabolic syndrome in humans and animals and to corresponding medicaments.
PCT/EP2006/006975 2005-07-15 2006-07-15 Use of substituted pyrazole compounds and combinations thereof for the treatment of the metabolic syndrome Ceased WO2007009701A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP05384014A EP1743637A1 (en) 2005-07-15 2005-07-15 Use of substituted pyrazole compounds and combinations thereof for the treatment of the metabolic syndrome
EP05384014 2005-07-15
US70545105P 2005-08-05 2005-08-05
US60/705,451 2005-08-05

Publications (2)

Publication Number Publication Date
WO2007009701A2 WO2007009701A2 (en) 2007-01-25
WO2007009701A3 true WO2007009701A3 (en) 2007-04-12

Family

ID=37595549

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/006975 Ceased WO2007009701A2 (en) 2005-07-15 2006-07-15 Use of substituted pyrazole compounds and combinations thereof for the treatment of the metabolic syndrome

Country Status (2)

Country Link
ES (1) ES2326723B1 (en)
WO (1) WO2007009701A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7923465B2 (en) 2005-06-02 2011-04-12 Glenmark Pharmaceuticals S.A. Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
FR2919184A1 (en) * 2007-07-26 2009-01-30 Sanofi Aventis Sa Use of 5-(4-chlorophennyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxylic acid as a medicament for treating e.g. chronic pain, neuropathic pain, inflammation, benign hypertrophy of the prostate and diabetic neuropathy
DE102008015032A1 (en) 2008-03-17 2009-09-24 Aicuris Gmbh & Co. Kg Substituted pyrazolamides and their use
DE102008015033A1 (en) 2008-03-17 2009-09-24 Aicuris Gmbh & Co. Kg Substituted (pyrazolyl-carbonyl) imidazolidinones and their use
DE102008062878A1 (en) 2008-12-17 2010-06-24 Aicuris Gmbh & Co. Kg Substituted furancarboxamides and their use
DE102008062863A1 (en) 2008-12-17 2010-06-24 Aicuris Gmbh & Co. Kg Substituted (thiophenyl-carbonyl) imidazolidinones and their use
DE102009036604A1 (en) 2009-07-30 2011-02-03 Aicuris Gmbh & Co. Kg Substituted bis-arylpyrazolamides with terminal primary amide functionality and their use
DE102011055815A1 (en) 2011-11-29 2013-05-29 Aicuris Gmbh & Co. Kg Carboxamide-substituted heteroaryl-pyrazoles and their use
DE102012016908A1 (en) 2012-08-17 2014-02-20 Aicuris Gmbh & Co. Kg Tris (hetero) aryl-pyrazoles and their use
WO2014174457A1 (en) 2013-04-23 2014-10-30 Council Of Scientific & Industrial Research Pyrazole carboxylic acid analogues as anti-mycobacterial drug candidates
WO2020113094A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1384477A1 (en) * 2001-04-06 2004-01-28 Laboratorios Del Dr. Esteve, S.A. Utilization of pyrazoline derivatives in the preparation of a medicament for the prevention and/or treatment of proliferative cell diseases
US20040122033A1 (en) * 2002-12-10 2004-06-24 Nargund Ravi P. Combination therapy for the treatment of obesity
WO2005077911A1 (en) * 2004-02-17 2005-08-25 Laboratorios Del Dr. Esteve S.A. Substituted pyrazoline compounds, their preparation and use as medicaments
WO2005077909A1 (en) * 2004-02-17 2005-08-25 Laboratorios Dr. Esteve S.A. Substituted pyrazoline compounds for reducing triglycerides in blood

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1384477A1 (en) * 2001-04-06 2004-01-28 Laboratorios Del Dr. Esteve, S.A. Utilization of pyrazoline derivatives in the preparation of a medicament for the prevention and/or treatment of proliferative cell diseases
US20040122033A1 (en) * 2002-12-10 2004-06-24 Nargund Ravi P. Combination therapy for the treatment of obesity
WO2005077911A1 (en) * 2004-02-17 2005-08-25 Laboratorios Del Dr. Esteve S.A. Substituted pyrazoline compounds, their preparation and use as medicaments
WO2005077909A1 (en) * 2004-02-17 2005-08-25 Laboratorios Dr. Esteve S.A. Substituted pyrazoline compounds for reducing triglycerides in blood

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"Der Begriff "Metabolisches Syndrom" ist unklar", DEUTSCHE APOTHEKER ZEITUNG, vol. 42, 20 October 2005 (2005-10-20), pages 8, XP002360775 *
ECKEL R H ET AL: "The metabolic syndrome", LANCET THE, LANCET LIMITED. LONDON, GB, vol. 365, no. 9468, 16 April 2005 (2005-04-16), pages 1415 - 1428, XP004849990, ISSN: 0140-6736 *
SIDDALL R: "RIO-DIABETES: RIMONABANT SHOWS PROMISE IN TYPE 2 DIABETES", BRITISH JOURNAL OF CARDIOLOGY, LONDON, GB, vol. 12, no. 4, July 2005 (2005-07-01), pages 257, XP009053958, ISSN: 0969-6113 *

Also Published As

Publication number Publication date
WO2007009701A2 (en) 2007-01-25
ES2326723B1 (en) 2010-05-11
ES2326723A1 (en) 2009-10-16

Similar Documents

Publication Publication Date Title
WO2007115821A3 (en) Organic compounds
EP1884513A4 (en) Pyrazole compound and therapeutic agent for diabetes comprising the same
IL198289A (en) Substituted dihydropyrazolones, processes for their preparation, medicaments comprising them and their use for the preparation of such medicaments
IL186616A0 (en) Spiro-oxindole compounds and their uses as therapeutic agents
IL177450A0 (en) Substituted pyrazoline compounds, their preparation and use as medicaments
IL186615A0 (en) Spiroheterocylic compounds and their uses as therapeutic agents
IL193467A0 (en) Substituted indazole derivatives, their manufacture and use as pharmaceutical agents
WO2007038459A3 (en) Carboxyamine compounds and their use in the treatment of hdac dependent diseases
IL198411A0 (en) Haloalkylsulfonanilide derivative or salt thereof, herbicide comprising the derivative as active ingredient, and use of the herbicide
IL189394A0 (en) Substituted pyrazolecarboxylic acid anilide derivatives and agricultural compositions containing the same
WO2008087367A3 (en) Substituted (phenylthiazolyl)-phenyl-propan-1-one and (phenyloxazodyl)-phenyl-propan-1-one derivatives, preparations and uses of same
EP2045253A4 (en) alpha-AMINO ACID DERIVATIVE AND PHARMACEUTICAL COMPRISING THE SAME AS ACTIVE INGREDIENT
WO2009071689A3 (en) 5-halogen-substituted oxindole derivatives and use thereof for treating vasopressine-dependent diseases
WO2008087366A3 (en) Substituted 3-phenyl-1-(phenylthienyl)propan-1-one and 3-phenyl-1-(phenylfuranyl)propan-1-one derivatives, and preparation and use of same
TW200745043A (en) Substituted pyrazoline compounds, their preparation and use as medicaments
WO2010077339A3 (en) β-ARRESTIN EFFECTORS AND COMPOSITIONS AND METHODS OF USE THEREOF
WO2007009701A3 (en) Use of substituted pyrazole compounds and combinations thereof for the treatment of the metabolic syndrome
TW200738699A (en) 4-Substituted pyrazoline compounds, their preparation and use as medicaments
IL186022A0 (en) Dermatological compositions and salts for the treatment of dermatological diseases
WO2007025146A3 (en) Balsalazide formulations and manufacture and use thereof
TWI372047B (en) Topical pain relief compositions of n,2,3-trimethyl-2-isopropylbutamide and methods for using the same
WO2007009686A3 (en) Substituted pyrazoline compounds, their preparation and use as medicaments
IL186851A0 (en) Styrylsulfonamides, their manufacture and use as pharmaceutical agents
ZA200710097B (en) Pyrazole compound and therapeutic agent for diabetes comprising the same
ZA201005394B (en) 15,16-methylene-17-hydroxy-19-nor-21-carboxylic acid y-lactone derivative,use thereof,and medicament containing said derivative

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 200850006

Country of ref document: ES

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: P200850006

Country of ref document: ES

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06762617

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 06762617

Country of ref document: EP

Kind code of ref document: A2

WWP Wipo information: published in national office

Ref document number: 200850006

Country of ref document: ES

Kind code of ref document: A

WWG Wipo information: grant in national office

Ref document number: 200850006

Country of ref document: ES

Kind code of ref document: A